Publications by authors named "Sheldon Leung"

Claim this Profile
R
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Takashi Kei Kishimoto, Max Fournier, Alicia Michaud, Gina Rizzo, Christopher Roy, Sheldon S Leung

J Autoimmun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
Petr O Ilyinskii, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capela, Sheldon S Leung

PNAS Nexus· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).
Alan Kivitz, Wesley DeHaan, Rehan Azeem, Justin Park, Sheri Rhodes, Sheldon S Leung

Rheumatol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Earl Sands, Alan Kivitz, Wesley DeHaan, Sheldon S Leung, Lloyd Johnston

Nat Commun· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia.
Petr O Ilyinskii, Alicia M Michaud, Gina L Rizzo, Christopher J Roy, Sheldon S Leung

Mol Ther Methods Clin Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles.
Petr O Ilyinskii, Alicia M Michaud, Christopher J Roy, Gina L Rizzo, Stephanie L Elkins, Sheldon S Leung

Sci Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplexed immunoassay approach to characterize antidrug antibody like specific reactivity.
Sheldon Leung, Corinna Fiorotti, Michael Bibik, David Brown, Martin A Gleeson

Bioanalysis· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioanalytical challenges and unique considerations to support pharmacokinetic characterization of bispecific biotherapeutics.
Mark Ma, Kelly Colletti, Tong-Yuan Yang, Sheldon Leung, Susan Pederson

Bioanalysis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.
Yao-Yun Fan, Lindsay B Avery, Mengmeng Wang, Denise M O'Hara, Sheldon Leung

MAbs· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity).
Lauren Stevenson, Lakshmi Amaravadi, Heather Myler, Laura Salazar-Fontana, Boris Gorovits, Sheldon Leung

Bioanalysis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics.
Alison P Joyce, Mengmeng Wang, Rosemary Lawrence-Henderson, Cynthia Filliettaz, Sheldon S Leung

Pharm Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein-based matrix interferences in ligand-binding assays.
Boris Gorovits, Jim McNally, Corinna Fiorotti, Sheldon Leung

Bioanalysis· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions in mice.
Yulia Vugmeyster, Yiqun Etran Zhang, Xiaotian Zhong, Jill Wright, Sheldon S Leung

Int Immunopharmacol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automate it: ligand-binding assay productivity in a discovery bioanalytical setting.
Sheldon S Leung, Elizabeth A Dreher

Bioanalysis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of response surface methods and path of steepest ascent to optimize ligand-binding assay sensitivity.
Alison P Joyce, Sheldon S Leung

J Immunol Methods· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery fit-for-purpose ligand-binding PK assays: what's really important?
Lindsay E King, Sheldon Leung, Chad Ray

Bioanalysis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.
Hendrik Neubert, Scott Fountain, Lindsay King, Tracey Clark, Yan Weng, Sheldon Leung

Bioanalysis· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ligand-binding assays in the 21st Century laboratory: recommendations for an automated data interchange process.
Sheldon S Leung, Joel Usansky, Robert Lynde, Theingi Thway, Robert Hendricks

AAPS J· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Getting from proto-sharing to sharing: collaborating on electronic solutions for ligand-binding assays.
Sheldon Leung

Bioanalysis· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis